Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2490313 | 0.92 | HRH3 (0.45) | MAP4K4KDM4ESMN1; SMN2HRH3KCNH2 | |
| SCHEMBL14507938 | 0.91 | HRH3 (0.49) | MAP4K4KDM4ESMN1; SMN2HRH3KCNH2 | |
| SCHEMBL12090211 | 0.82 | MAP4K4 (0.49) | MAP4K4KDM4ESMN1; SMN2HRH3KCNH2 | |
| SCHEMBL17896397 | 0.82 | HRH3 (0.42) | MAP4K4SMN1; SMN2HRH3KCNH2CYP2D6 | |
| SCHEMBL17896406 | 0.79 | HRH3 (0.38) | KDM4ESMN1; SMN2HRH3KCNH2 | |
| SCHEMBL18135270 | 0.79 | MAP4K4 (0.48) | MAP4K4SMN1; SMN2HRH3KCNH2LMNA | |
| SCHEMBL2603279 | 0.77 | HRH3 (0.59) | HRH3KCNH2CYP3A4CYP2D6LMNA | |
| SCHEMBL8302404 | 0.77 | KDM4E (0.50) | MAP4K4KDM4ESMN1; SMN2HRH3KCNH2 | |
| SCHEMBL21004260 | 0.77 | MAP4K4 (0.46) | MAP4K4KDM4ESMN1; SMN2HRH3KCNH2 | |
| SCHEMBL17886915 | 0.77 | MAP4K4 (0.46) | MAP4K4KDM4ESMN1; SMN2HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9873709-B2 | Triazolopyridine compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | FLT4, FLT1, KDR | MAP4K4 662/4885KDM4E 1052/4885SMN1; SMN2 3026/4885 |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | MAP4K4 27/4885KDM4E 1708/4885SMN1; SMN2 3249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.